retatrutide phase 2 trial obesity triple agonist hormone receptor for metabolic dysfunction-associated steatotic liver disease: a randomized 2a Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Pay in 4 interest-free payments of $7.04 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28

























